Pharma and Food: Why the Registry is Stricter with “Heightened Vigilance” Categories

Trade mark applications for pharmaceuticals, medicinal preparations, and food products face a more rigorous standard of scrutiny in India than applications for other goods. The Registry and the courts apply what is often called a “heightened vigilance” standard, recognising that confusion between marks in these categories can have serious public health consequences. On top of this, Section 13 of the Trade Marks Act imposes a hard bar against registering certain pharmaceutical names.

The Heightened Vigilance Doctrine

The leading authority on this principle is the Supreme Court’s decision in Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., which established that a stricter standard of comparison must be applied when assessing similarity between pharmaceutical trade marks. The Court reasoned that confusion between drug names can lead to patients receiving the wrong medication, with potentially life-threatening consequences.

Under this doctrine, the threshold for finding similarity is lower than for ordinary consumer goods. Marks that might coexist comfortably in other product categories may be refused or found infringing in the pharmaceutical space. The Registry applies a broader net when identifying phonetic or structural similarities, and is less willing to accept arguments that minor visual or conceptual differences overcome phonetic overlap.

Factors Specific to Pharmaceutical Marks

The heightened vigilance standard takes into account several factors unique to the pharmaceutical context:

• The consumer: Purchasers of medicines include not only literate urban consumers but also semi-literate or rural populations who may rely heavily on the sound of a drug name rather than its written form.
• The point of sale: Medicines are frequently requested orally at pharmacy counters, where the pharmacist may select a product based on what they hear rather than what they read.
• The consequence of confusion: A wrong product selection in pharmaceutical goods can cause serious harm, including adverse drug reactions, treatment failure, or death.
• Self-medication: In India, many consumers purchase medicines without a doctor’s prescription, increasing the risk that they will rely on brand name recognition alone.

Application to Food Products

While the Cadila decision focused on pharmaceuticals, the heightened vigilance principle has been extended to food products and other ingestible goods. The rationale is the same: confusion between brands of food, beverages, or nutritional supplements can lead to unintended consumption of allergens, incorrect dosages, or exposure to ingredients that are harmful to specific populations. The Registry treats these categories with similar caution.

Section 13: The INN Bar

Section 13 of the Trade Marks Act imposes a separate, absolute bar on certain chemical and pharmaceutical names. It provides that:

• No trade mark shall be registered that consists of, or contains, the commonly used and accepted name of any single chemical element or compound in relation to a chemical substance or preparation.
• No word that has been declared by the World Health Organization (WHO) as an International Non-proprietary Name (INN) shall be registered as a trade mark. Registration is also refused if the Registrar determines that the mark is deceptively similar to an INN.

This provision applies to all applications filed under Class 5 (pharmaceuticals). The Indian Trade Marks Registry maintains a list of declared INNs, and all Class 5 applications are screened against this list. The INN bar cannot be overcome by evidence of use or acquired distinctiveness — it is an absolute prohibition.

In Cadila Laboratories Ltd. v. Burroughs Wellcome India Ltd., the mark “CYLCOVIR” in Class 5 was denied registration because it was found confusingly similar to “ACYCLOVIR,” an International Non-proprietary Name for a pharmaceutical substance.

Practical Implications

The heightened vigilance standard and the INN bar together create a significantly more restrictive environment for pharmaceutical and food trade marks in India:

• Phonetic similarity is given even greater weight: Small phonetic differences that might save a mark in other categories are insufficient for pharmaceuticals.
• Broader similarity assessments: Marks sharing a common prefix, suffix, or structural pattern may be refused, even where an ordinary-goods comparison would find them distinct.
• INN screening is mandatory: Any mark that incorporates or closely resembles an INN stem will be rejected for Class 5 goods.
• Opposition risk is elevated: Pharmaceutical companies actively monitor and oppose applications that approach their existing marks.

Strategic Recommendations

• Screen against the INN list: Before finalising a pharmaceutical brand name, check it against the WHO’s published list of International Non-proprietary Names and their stems.
• Apply a stricter internal similarity standard: When clearing pharmaceutical marks, use a lower threshold for phonetic similarity than you would for ordinary consumer goods.
• Choose maximally distinctive names: Coined words with no phonetic resemblance to existing pharmaceutical marks or INN stems offer the safest path.
• Consider the consumer profile: Assess how the mark will be perceived and communicated by the full range of Indian consumers, including those with limited literacy.
• Maintain comprehensive records: Document every aspect of your pharmaceutical brand’s development, including the rationale for name selection, linguistic analysis, and screening against existing marks and INN stems.

Common Mistakes

• Applying general-goods clearing standards: Pharmaceutical applicants who clear marks using the same similarity threshold as consumer goods will miss conflicts that the Registry will catch under the heightened vigilance standard.
• Ignoring INN stems: The WHO publishes not only complete INNs but also common stems used in naming pharmaceutical compounds. A mark that incorporates a common INN stem (such as “-vir” for antivirals or “-mab” for monoclonal antibodies) will face objection even if it is not identical to any specific INN.
• Underestimating oral communication: In the Indian market, medicines are frequently requested and dispensed by sound. A mark that is visually distinct but phonetically similar to an existing pharmaceutical brand creates genuine risk.
• Failing to differentiate packaging: Even where marks are cleared for registration, similar-sounding pharmaceutical brands should use visually distinct packaging to reduce confusion at the point of sale.

Key Takeaway

India applies a heightened vigilance standard to pharmaceutical and food trade marks, reflecting the serious public health consequences of brand confusion in these categories. The threshold for finding similarity is lower, phonetic overlap is scrutinised more strictly, and Section 13 imposes an absolute bar on marks that incorporate or resemble International Non-proprietary Names. For applicants in these sectors, the margin for error is significantly narrower than in other product categories.